[Application of double plasma molecular adsorption system in children with acute liver failure]
- PMID: 33627215
- PMCID: PMC7921536
- DOI: 10.7499/j.issn.1008-8830.2010145
[Application of double plasma molecular adsorption system in children with acute liver failure]
Abstract
Objective: To study the efficacy and safety of double plasma molecular absorption system (DPMAS) in the treatment of pediatric acute liver failure (PALF).
Methods: A prospective analysis was performed on the medical data of children with PALF who were hospitalized in the Intensive Care Unit (ICU), Hunan Children's Hospital, from March 2018 to June 2020. The children were randomly divided into two groups:plasma exchange group (PE group) and DPMAS group (n=18 each). The two groups were compared in terms of clinical indices after treatment, laboratory markers before and after treatment, and adverse events after treatment.
Results: Compared with the PE group, the DPMAS group had a significantly lower number of times of artificial liver support therapy and a significantly shorter duration of ICU stay (P < 0.05), while there was no significant difference in the 12-week survival rate between the two groups (P > 0.05). There was no significant difference in laboratory markers between the two groups before treatment (P > 0.05). After treatment, both groups had reductions in the levels of total bilirubin, interleukin-6, and tumor necrosis factor-α, and the DPMAS group had significantly greater reductions than the PE group (P < 0.05). Both groups had a significant reduction in alanine aminotransferase (P < 0.05), while there was no significant difference between the two groups (P > 0.05). The PE group had a significant increase in albumin, while the DPMAS group had a significant reduction in albumin (P < 0.05). The PE group had a significant reduction in prothrombin time, while the DPMAS group had a significant increase in prothrombin time (P < 0.05). There was no significant difference between the two groups in the rebound rate of total bilirubin and the overall incidence rate of adverse events after treatment (P > 0.05).
Conclusions: DPMAS is safe and effective in the treatment of PALF and can thus be used as an alternative to artificial liver support therapy.
目的: 探讨双重血浆分子吸附系统(DPMAS)用于儿童急性肝衰竭(PALF)的有效性及安全性。
方法: 前瞻性收集2018年3月至2020年6月在湖南省儿童医院重症医学科住院的PALF患儿的临床资料,随机分为血浆置换组(PE组)和DPMAS组,每组各18例。比较两组患儿临床指标、治疗前后实验室指标和不良反应。
结果: DPMAS组人工肝次数、ICU住院时间均小于PE组(P < 0.05),两组12周生存率比较差异无统计学意义(P > 0.05)。两组治疗前实验室指标比较差异无统计学意义(P > 0.05)。两组治疗后总胆红素、白细胞介素-6、肿瘤坏死因子-α较治疗前均下降,DPMAS组下降更显著(P < 0.05);两组治疗后丙氨酸氨基转移酶较治疗前均下降(P < 0.05),但组间差异无统计学意义(P > 0.05);PE组治疗后白蛋白较治疗前上升,而DPMAS组较治疗前降低(P < 0.05);PE组治疗后凝血酶原时间较治疗前缩短,而DPMAS组较治疗前延长(P < 0.05)。两组治疗后总胆红素反弹率差异无统计学意义(P > 0.05)。两组间不良反应总发生率差异无统计学意义(P > 0.05)。
结论: DPMAS治疗PALF有效且安全,可作为PALF人工肝治疗时的备选新模式。
Similar articles
-
Combination of Plasma Exchange and Adsorption Versus Plasma Exchange in Pediatric Acute Liver Failure: A Multicenter Cohort Study.J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):710-715. doi: 10.1097/MPG.0000000000003759. Epub 2023 Mar 12. J Pediatr Gastroenterol Nutr. 2023. PMID: 36913704
-
Artificial liver support system in pediatric acute liver failure due to mushroom poisoning: Case series.Ann Hepatol. 2021 Jul-Aug;23:100290. doi: 10.1016/j.aohep.2020.100290. Epub 2020 Nov 19. Ann Hepatol. 2021. PMID: 33221398
-
Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure.J Clin Apher. 2019 Aug;34(4):392-398. doi: 10.1002/jca.21690. Epub 2019 Feb 13. J Clin Apher. 2019. PMID: 30758886 Free PMC article.
-
The Clinical Efficacy of Double Plasma Molecular Absorption System Combined with Plasma Exchange in the Treatment of Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.J Healthc Eng. 2022 Mar 25;2022:3139929. doi: 10.1155/2022/3139929. eCollection 2022. J Healthc Eng. 2022. PMID: 35368957 Free PMC article.
-
Non-bioartificial liver support system in the treatment of pediatric acute liver failure.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025 Feb 28;50(2):266-274. doi: 10.11817/j.issn.1672-7347.2025.240184. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025. PMID: 40523769 Review. Chinese, English.
Cited by
-
Development and validation of a machine learning model to predict prognosis in liver failure patients treated with non-bioartificial liver support system.Front Med (Lausanne). 2024 Mar 13;11:1368899. doi: 10.3389/fmed.2024.1368899. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38545509 Free PMC article.
-
Severe acute hepatitis of unknown causes in children - Current findings, questions, opinions, and recommendations, a mini-review.Pediatr Investig. 2022 Jul 11;6(3):211-218. doi: 10.1002/ped4.12336. eCollection 2022 Sep. Pediatr Investig. 2022. PMID: 36203518 Free PMC article. Review.
-
[Therapeutic plasma exchange in the pediatric intensive care unit: a single-center retrospective study].Zhongguo Dang Dai Er Ke Za Zhi. 2022 Oct 15;24(10):1149-1153. doi: 10.7499/j.issn.1008-8830.2204172. Zhongguo Dang Dai Er Ke Za Zhi. 2022. PMID: 36305117 Free PMC article. Chinese.
-
Preliminary experience of combined dual plasma molecular adsorption system and plasma exchange in pediatric acute liver failure: a retrospective case series.BMC Pediatr. 2025 Mar 3;25(1):163. doi: 10.1186/s12887-025-05520-z. BMC Pediatr. 2025. PMID: 40033216 Free PMC article.
-
Acetaminophen Poisoning: Case Reports of Early Liver Dialysis for Hepatic Injury.Clin Case Rep. 2025 Jul 17;13(7):e70642. doi: 10.1002/ccr3.70642. eCollection 2025 Jul. Clin Case Rep. 2025. PMID: 40677300 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources